EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
NEW YORK, Oct. 25, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its third quarter 2017 financial results prior to the NASDAQ market open on November 1, 2017. Intercept management will conduct a conference call and audio webcast on Wednesday, November 1, 2017 at 8:30 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conference:
- Credit Suisse 26th Annual Healthcare Conference on November 7, 2017 at 4:30 p.m. Pacific Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT:
For more information about Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
